Drug-induced nail abnormalities

Expert Opinion on Drug Safety

Volumn 3, Issue 1, 2004, Pages 57-65

  Piraccini, Bianca Maria ^a   Iorizzo, Matilde ^a   Antonucci, Angela ^a   Tosti, Antonella ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Drugs; Nails; Side effects; Toxicity

Indexed keywords

ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CEFALORIDINE; CLOXACILLIN; CYCLOSPORIN DERIVATIVE; DAPSONE; DITHRANOL; FLUORINE; HEPARIN; HYDANTOIN; ITRACONAZOLE; LEVODOPA; LITHIUM; METHOTREXATE; METOPROLOL; OXCARBAZEPINE; PENICILLAMINE; PSORALEN DERIVATIVE; RETINOID DERIVATIVE; SULFONAMIDE; TAXANE DERIVATIVE; TETRACYCLINE DERIVATIVE; TRIMETHADIONE; UNINDEXED DRUG; VALPROIC ACID; WARFARIN; ZIDOVUDINE; DRUG;

ATROPHY; BEAU LINE; BLEEDING; BLOOD VESSEL; DRUG CLASSIFICATION; DRUG TOXICITY; GROWTH DISORDER; HUMAN; ISCHEMIA; LEUKONYCHIA; MANUAL LABOR; MELANONYCHIA; NAIL BED; NAIL DISEASE; NAIL PIGMENTATION; ONYCHOLYSIS; ONYCHOMADESIS; PAIN; PARONYCHIA; PYOGENIC GRANULOMA; REVIEW; SKIN APPENDAGE DISEASE; SYMPTOMATOLOGY; TERATOGENESIS; BLOOD FLOW; CHEMICALLY INDUCED DISORDER; NAIL; PATHOLOGY; PIGMENT DISORDER; VASCULARIZATION;

HUMANS; NAIL DISEASES; NAILS; NAILS, MALFORMED; PHARMACEUTICAL PREPARATIONS; PIGMENTATION DISORDERS; REGIONAL BLOOD FLOW;

EID: 1842537195     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.3.1.57     Document Type: Review

References (46)

1. TOSTI A, BARAN R, DAWBER RP: The nail in systemic diseases and drug-induced changes. In: Baran and Dawber's Diseases of the Nails and their Management (2nd edn). Baran R, Dawber RP, de Berker DA et al. (Eds), Blackwell Science, Oxford (2001):223-329.
2. DANIEL CR III, SCHER RK: Nail changes secondary to systemic drugs or ingestans. J. Am. Acad. Dermatol. (1984) 10(2):250-258.
3. PIRACCINI BM, TOSTI A: Drug-induced nail disorders. Incidence, management and prognosis. Drug Saf. (1999) 21(3):187-201.
4. PIRACCINI BM, IORIZZO M, TOSTI A: Drug-induced nail abnormalities. Am. J. Clin. Dermatol. (2003) 4(1):31-37.
5. BALTENNECK F, GARSON JC, ENGSTROM P et al.: Study of the keratinization process in human hair follicle by X-ray microdiffraction. Cell Mol. Biol. (Noisy-le-grand) (2000) 46(5):1017-1024.
6. PETTIFOR JM, BENSON R: Congenital malformations associated with the administration of oral anticoagulants during pregnancy. J. Pediatr. (1975) 86(3):459-462.
7. HOLMES LB, HARVEY EA, BROWN KS, HAYES AM, KHOSHBIN S: Anti-convulsant teratogenesis: I. A study design for newborn infants. Teratology (1994) 49(3):202-207.
8. MINISINI AM, TOSTI A, SOBRERO AF et al.: Taxane-induced nail changes: incidence, clinical presentation and outcome. Ann. Oncol. (2003) 14(2):333-337.
9. BARAN R: Retinoids and the nail. J. Dermatol. Treat. (1990) 1:51-154.
10. EASTWOOD JB, CURTIS JR, SMITH EK, DE WARDENER HE: Shedding of nails apparently induced by the administration of large amounts of cephaloridine and cloxacillin in two anephric patients. Br. J. Dermatol. (1969) 81(10):750-752.
11. CHEN HH, LIAO YH: Beau's lines associated with itraconazole. Acta Derm. Venereol. (2002) 82(5):398.
12. DONCKER PD, PIERARD GE: Acquired nail beading in patients receiving itraconazole - an indicator of faster nail growth? A study using optical profilometry. Clin. Exp. Dermatol. (1994) 19(5):404-406.
13. MILLER E: Levodopa and nail growth. New Engl. J. Med. (1973) 288(17):916.
14. CHAPMAN S, COHEN PR: Transverse leukonychia in patients receiving cancer chemotherapy. South Med. J. (1997) 90(4):395-398.
15. SHELLEY WB, HUMPREY GB: Transverse leukonychia (Mees' lines) due to daunorubicin chemotherapy. Pediatr. Dermatol. (1997) 14(2):144-145.
16. BARAN R, JUHLIN L: Photoonycholysis. Photodermatol. Photoimmunol. Photomed. (2002) 18:202-207.
17. HUSSAIN S, ANDERSON DN, SALVATTI ME, ADAMSON B, MCMANUS M, BRAVERMAN AS: Onycholysis as a complication of systemic chemotherapy: report of five cases associated with prolonged weekly paclitaxel therapy and review of the literature. Cancer (2000) 88(10):2367-2371.
18. WASNER G, HILPERT F, BARON R, PFISTERER J: Nail changes secondary to docetaxel. Lancet (2001) 357:910.
19. CHANG JC: Acute bullous dermatosis and onycholysis due to high-dose methotrexate and leucovorin calcium. Arch. Dermatol. (1987) 123(8):990-992.
20. GAYLIS N: Infliximab in the treatment of an HIV positive patient with Reiter's syndrome. J. Rheumatol. (2003) 30(2):407-411.
21. WANTZIN GL, THOMSEN K: Acute paronychia after high-dose methotrexate therapy. Arch. Dermatol. (1983) 119(7):623-624.
22. ZERBONI R, ANGIUS AG, CUSINI M, TARANTINI G, CARMINATI G: Lamivudine-induced paronychia. Lancet (1998) 351(9111):1256.
23. TOSTI A, PIRACCINI BM, D'ANTUONO A, MARZADURI S, BETTOLI V: Paronychia associated with antiretroviral therapy. Br. J. Dermatol. (1999) 140(5):1165-1168.
24. BLUMENTAL G: Paronychia and pyogenic granuloma-like lesions with isotretinoin. J. Am. Acad. Dermatol. (1984) 10(4):677-678.
25. BOUSCARAT F, BOUCHARD C, BOUHOUR D: Paronychia and pyogenic granuloma of the great toes in patients with indinavir. N. Engl. J. Med. (1998) 338(24):1776-1777.
26. CALISTA D, BOSCHINI A: Cutaneous side effects induced by indinavir. Eur. J. Dermatol. (2000) 10(4):292-296.
27. BUSAM KJ, CAPODIECI P, MOTZER R, KIEHN T, PHELAN D, HELPERN AC: Cutaneous side effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br. J. Dermatol. (2001) 144(6):1169-1176.
28. BOUCHER KW, DAVIDSON K, MIRAKHUR B, GOLDBERG J, HEYMANN WR: Paronychia induced by cetuximab an antiepidermal growth factor receptor antibody. J. Am. Acad. Dermatol. (2002) 47(4):632-633.
29. NAKANO J, NAKAMURA M. Paronychia induced by gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J. Dermatol. (2003) 30(3):261-262.
30. MALONEY DM, SCHMIDT JD, DUVIC M: Alitretinoin gel to treat pyogenic granuloma. J. Am. Acad. Dermatol. (2002) 47(6):969-970.
31. STRINGER MD, BENTLEY PG: Peripheral gangrene associated with β-blockade. Br. J. Surg. (1986) 73(12):1008.
32. SNAUWAERT J, DEGREEF H: Bleomycin-induced Raynaud's phenomenon and acral sclerosis. Dermatologica (1984) 169(4):172-174.
33. VAROTTI C, GHETTI E, PIRACCINI BM et al.: Subungual hematoma in a patient treated with in oral anticoagulant (warfarin sodium). Eur. J. Dermatol. (1997) 7(5):395-396.
34. GHETTI E, PIRACCINI BM, TOSTI A: Onycholysis and subungual haemorrhages secondary to systemic chemotherapy (paclitaxel). J. Eur. Acad. Dermatol. Venereol. (2003) 17(4):459-460.
35. LORENZI S, D'ANTUONO A, IORIZZO M, TOSTI A: Skin rash and splinter haemorrhages from ganciclovir. J. Dermatol. Treat. (2003) 14(3):177-178.
36. WOLF R, TUR E, BRENNER S: Corticosteroid-induced 'disappearing digit'. J. Am. Acad. Dermatol. (1990) 23(4 Pt 1):755-756.
37. BARAN R, KECHIJIAN P: Longitudinal melanonychia: diagnosis and management J. Am. Acad. Dermatol. (1989) 21(6):1165-1175.
38. NIXON DW: Alterations in nail pigment with cancer chemotherapy. Arch. Int. Med. (1976) 136(10):1117-1118.
39. ASTE N, FUMO G, CONTU F, BIGGIO P: Nail pigmentation caused by hydroxyurea: report of 9 cases. J. Am. Acad. Dermatol. (2002) 47(1):146-147.
40. LEDBETTER LS, HSU S: Melanonychia associated with PUVA therapy. J. Am. Acad. Dermatol. (2003) 48(2 Suppl. 1):31-32.
41. SHELLEY WB, RAWNSLEY HM, PILLSBURY DM: Postirradiation melanonychia. Arch. Dermatol. (1964) 90:174-176.
42. HENDRICKS AA: Yellow lunulae with fluorescence after tetracycline therapy. Arch. Dermatol. (1980) 116(4):438-440.
43. FAM AG, PATON TW: Nail pigmentation after parenteral gold therapy for rheumatoid arthritis: 'gold nails'. Arthr. Rheum. (1984) 27(1):119-120.
44. TOSTI A, PIRACCINI BM, GUERRA L: Reversible melanonychia due to clofazimine. 18th World Congress of Dermatology, New York, USA (1992) 183. Abstract.
45. KIMYAI-ASADI A, JIH MH: Minocycline induced nail-bed pigmentation. J. Drugs Dermatol. (2002) 1(2):197-198.
46. TUFFANELLI D, ABRAHAM RK, DUBOIS EI: Pigmentation from antimalarial therapy. Arch. Dermatol. (1963) 88:419-426.